rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-236-241rsp-3326Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL OBSERVATIONПрименение Анакинры у пациента с сочетанием двух аутовоспалительных заболеваний: семейной средиземноморской лихорадки и подагрыThe use of Anakinra in a patient with a combination of two autoinflammatory diseases: Familial Mediterranean fever and gouthttps://orcid.org/0000-0003-1191-5831ЕлисеевМ. С.EliseevM. S.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

elicmax@yandex.ruhttps://orcid.org/0000-0002-5394-7869ЖелябинаО. В.ZheliabinaO. V.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а;119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2

https://orcid.org/0000-0002-4383-9872ЧеремушкинаЕ. В.CheremushkinaE. V.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-0394-9249КоротковаТ. А.KorotkovaT. A.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202328042023612236241Copyright © Елисеев М.С., Желябина О.В., Насонов Е.Л., Черемушкина Е.В., Короткова Т.А., Паневин Т.С., 20232023Елисеев М.С., Желябина О.В., Насонов Е.Л., Черемушкина Е.В., Короткова Т.А., Паневин Т.С.Eliseev M.S., Zheliabina O.V., Nasonov E.L., Cheremushkina E.V., Korotkova T.A., Panevin T.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3326

В настоящее время подагра рассматривается как аутовоспалительное заболевание наряду с семейной средиземноморской лихорадкой (ССЛ). Общность базовых механизмов воспаления, лежащих в патогенезе ССЛ и подагры, предопределяет возможность применения и схожих видов терапии, направленной на купирование и профилактику приступов, включая назначение колхицина и ингибиторов интерлейкина (ИЛ) 1. Представлен клинический случай сочетания ССЛ и подагры. Пациенту была назначена анакинра, доказавшая свою эффективность в лечении как ССЛ, так и подагры. Терапия ингибитором ИЛ-1 полностью оправдала ожидания: уже после первой инъекции анакинры у пациента уменьшились припухлость и интенсивность болей в суставах.

Along with familial Mediterranean fever (FMF), it is now considered an autoinflammatory disease and gout. The commonality of the basic mechanisms of inflammation underlying the pathogenesis of FMF and gout predetermines the possibility of using similar therapies aimed at stopping and preventing seizures (colchicine and IL-1 inhibitors). A clinical case is presented describing the presence of a combination of FMF and gout in a patient. The patient was prescribed anakinra, which proved to be effective both as a treatment for FMF and gout. The appointment of an IL-1 inhibitor fully justified expectations: already after the first injection of anakinra, the intensity of swelling and pain in the joints decreased in the patient.

средиземноморская лихорадкаподаграинтерлейкин 1анакинраMediterranean fevergoutinterleukin 1anakinraReferencesMcGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):297. doi: 10.1371/journal.pmed.0030297McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):297. doi: 10.1371/journal.pmed.0030297Peckham D, Scambler T, Savic S, McDermott MF. The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol. 2017;241(2):123-139. doi: 10.1002/path.4812Peckham D, Scambler T, Savic S, McDermott MF. The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol. 2017;241(2):123-139. doi: 10.1002/path.4812McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-144. doi: 10.1016/s0092-8674(00)80721-7McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-144. doi: 10.1016/s0092-8674(00)80721-7Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med. 2010;21(3):157-163. doi: 10.1016/j.ejim.2010.03.005Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med. 2010;21(3):157-163. doi: 10.1016/j.ejim.2010.03.005Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832-842. doi: 10.1038/ni.3777Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832-842. doi: 10.1038/ni.3777Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319-325. doi: 10.1016/s1074-7613(04)00046-9Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319-325. doi: 10.1016/s1074-7613(04)00046-9Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi: 10.14412/1995-4484-2016-60-77Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.). doi: 10.14412/1995-4484-2016-60-77Klück V, Liu R, Joosten LAB. The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine. 2021;88(2):105092. doi: 10.1016/j.jbspin.2020.105092Klück V, Liu R, Joosten LAB. The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine. 2021;88(2):105092. doi: 10.1016/j.jbspin.2020.105092Елисеев МС, Чикина МН, Новикова АМ. Применение колхицина при подагре. Медицинский совет. 2021;(10):148-153. doi: 10.21518/2079-701X-2021-10-148-153Eliseev MS, Chikina MN, Novikova AM. Colchicine for gout. Medical Council. 2021;(10):148-153 (In Russ.). doi: 10.21518/2079-701X-2021-10-148-153Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-609. doi: 10.14412/1995-4484-2017-600-609Eliseev MS. Updated EULAR guidelines for the management of gout. Comments on certain items. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):600-609 (In Russ.). doi: 10.14412/1995-4484-2017-600-609Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621-668. doi: 10.1146/annurev.immunol.25.022106.141627Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621-668. doi: 10.1146/annurev.immunol.25.022106.141627Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90(4):797-807. doi: 10.1016/s0092-8674(00)80539-5Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90(4):797-807. doi: 10.1016/s0092-8674(00)80539-5Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA. 2006;103(26):9982-9987. doi: 10.1073/pnas.0602081103Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA. 2006;103(26):9982-9987. doi: 10.1073/pnas.0602081103Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol. 2009;146(5):467-478. doi: 10.1111/j.1365-2141.2009.07733.xChae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol. 2009;146(5):467-478. doi: 10.1111/j.1365-2141.2009.07733.xChae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112(5):1794-1803. doi: 10.1182/blood-2008-01-134932Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112(5):1794-1803. doi: 10.1182/blood-2008-01-134932Melikoglu MA. Two birds with one stone: Anakinra for both gout and familial Mediterranean fever attacks in a patient with renal transplant. Nefrologia (Engl Ed). 2020;40(6):680. doi: 10.1016/j.nefro.2019.11.008Melikoglu MA. Two birds with one stone: Anakinra for both gout and familial Mediterranean fever attacks in a patient with renal transplant. Nefrologia (Engl Ed). 2020;40(6):680. doi: 10.1016/j.nefro.2019.11.008Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, et al. Anakinra for colchicine-resistant familial Mediterranean fever: A random ized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2017;69(4):854-862. doi: 10.1002/art.39995Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, et al. Anakinra for colchicine-resistant familial Mediterranean fever: A random ized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2017;69(4):854-862. doi: 10.1002/art.39995Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: A randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: A randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227-253. doi: 10.1016/0002-9343(67)90167-2Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227-253. doi: 10.1016/0002-9343(67)90167-2Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12(1):72-76. doi: 10.1016/j.autrev.2012.07.025Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12(1):72-76. doi: 10.1016/j.autrev.2012.07.025Gögebakan H, Akkececi NS, Cetin GY. Relationship between metabolic syndrome and uric acid levels in patients with familial Mediterranean fever. Arch Iran Med. 2019;22(10):566-573.Gögebakan H, Akkececi NS, Cetin GY. Relationship between metabolic syndrome and uric acid levels in patients with familial Mediterranean fever. Arch Iran Med. 2019;22(10):566-573.Елисеев МС, Барскова ВГ. Метаболический синдром и подагра. Вестник Российской академии медицинских наук. 2008;(6):29-32.Eliseev MS, Barskova VG. Metabolic syndrome and gout. Bulletin of the Russian Academy of Medical Sciences. 2008;(6):29-32 (In Russ.).Kozan M, Ozan ZT, Demir V, Ede H. The relation of novel cardiovascular risk parameters in patients with familial Mediterranean fever. JRSM Cardiovasc Dis. 2019;8:2048004018823856. doi: 10.1177/2048004018823856Kozan M, Ozan ZT, Demir V, Ede H. The relation of novel cardiovascular risk parameters in patients with familial Mediterranean fever. JRSM Cardiovasc Dis. 2019;8:2048004018823856. doi: 10.1177/2048004018823856Елисеев МС, Денисов ИС, Маркелова ЕИ, Глухова СИ, Насонов ЕЛ. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: Результаты 7-летнего проспективного исследования. Терапевтический архив. 2017;89(5):10-19. doi: 10.17116/terarkh201789510-19Eliseev MS, Denisov IS, Markelova EI, Glukhova SI, Nasonov EL. Independent risk factors for severe cardiovascular events in male patients with gout: Results of a 7-year prospective study. Terapevticheskii arkhiv. 2017;89(5):10-19 (In Russ.). doi: 10.17116/terarkh201789510-19Yüksel S, Ayvazyan L, Gasparyan AY. Familial Mediterranean fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J. 2010;4:51-56. doi: 10.2174/1874192401004020051Yüksel S, Ayvazyan L, Gasparyan AY. Familial Mediterranean fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J. 2010;4:51-56. doi: 10.2174/1874192401004020051Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al.; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847. doi: 10.1056/NEJMoa2021372Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al.; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847. doi: 10.1056/NEJMoa2021372Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: A cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-1679. doi: 10.1136/annrheumdis-2015-207984Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: A cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-1679. doi: 10.1136/annrheumdis-2015-207984Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001;3(1):9-12.Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001;3(1):9-12.Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, et al. Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018;71(21):2405-2414. doi: 10.1016/j.jacc.2018.03.490Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, et al. Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018;71(21):2405-2414. doi: 10.1016/j.jacc.2018.03.490Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-542. doi: 10.7326/M18-1167Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-542. doi: 10.7326/M18-1167Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619-628. doi: 10.1161/CIRCIMAGING.113.001193Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619-628. doi: 10.1161/CIRCIMAGING.113.001193Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: A retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. doi: 10.1186/ar4303Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: A retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. doi: 10.1186/ar4303Neogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: An internet-based case-crossover study. Am J Med. 2014;127(4):311-318. doi: 10.1016/j.amjmed.2013.12.019Neogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: An internet-based case-crossover study. Am J Med. 2014;127(4):311-318. doi: 10.1016/j.amjmed.2013.12.019Balkarli A, Tepeli E, Balkarli H, Kaya A, Cobankara V. A variant allele of the Mediterranean-fever gene increases the severity of gout. Int J Rheum Dis. 2018;21(1):338-346. doi: 10.1111/1756-185X.12872Balkarli A, Tepeli E, Balkarli H, Kaya A, Cobankara V. A variant allele of the Mediterranean-fever gene increases the severity of gout. Int J Rheum Dis. 2018;21(1):338-346. doi: 10.1111/1756-185X.12872Sari I, Simsek I, Tunca Y, Kisacik B, Erdem H, Pay S, et al. Existe uma relação entre a artrite gotosa e as mutações genéticas da febre familiar do Mediterrâneo? [Is there a relationship between gouty arthritis and Mediterranean fever gene mutations?]. Rev Bras Reumatol. 2015;55(4):325-329 (In Portuguese). doi: 10.1016/j.rbr.2014.10.008Sari I, Simsek I, Tunca Y, Kisacik B, Erdem H, Pay S, et al. Existe uma relação entre a artrite gotosa e as mutações genéticas da febre familiar do Mediterrâneo? [Is there a relationship between gouty arthritis and Mediterranean fever gene mutations?]. Rev Bras Reumatol. 2015;55(4):325-329 (In Portuguese). doi: 10.1016/j.rbr.2014.10.008Salehzadeh F, Mohammadikebar Y, Haghi RN, Asl SH, Enteshary A. Familial Mediterranean fever gene mutations and gout as an auto-inflammatory arthropathy. Med Arch. 2019;73(1):55-57. doi: 10.5455/medarh.2019.73.55-57Salehzadeh F, Mohammadikebar Y, Haghi RN, Asl SH, Enteshary A. Familial Mediterranean fever gene mutations and gout as an auto-inflammatory arthropathy. Med Arch. 2019;73(1):55-57. doi: 10.5455/medarh.2019.73.55-57Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jéru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27(5):1898-1901. doi: 10.1093/ndt/gfr528Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jéru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27(5):1898-1901. doi: 10.1093/ndt/gfr528Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29(2):209-210. doi: 10.1007/s10067-009-1279-8Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29(2):209-210. doi: 10.1007/s10067-009-1279-8Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24(2):676-678. doi: 10.1093/ndt/gfn646Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24(2):676-678. doi: 10.1093/ndt/gfn646Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11(10):897-904. doi: 10.1038/ni.1935Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11(10):897-904. doi: 10.1038/ni.1935

The authors declare that there are no conflicts of interest present.